NCT07723716已完成3 期
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-design, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 167
- 试验地点
- 1
- 主要终点
- Percentage of Participants Gaining 3 Lines or More in DCNVA
研究概览
简要总结
This study was to compare the presbyopia correction effect between the treatment group and the control group, evaluated by the proportion of patients who achieved an improvement of 3 lines or more in mesopic binocular DCNVA at post-dose after 4 weeks of administration of the investigational product.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged ≥40 years and <65 years.
- •Patients who meet all of the following visual acuity assessment criteria:
- •① DCNVA between 20/100 and 20/40 (Snellen equivalent).
- •② CDVA of 20/25 or better (Snellen equivalent).
- •Patients who are capable of performing all study procedures, including questionnaires and examinations, and willing to cooperate with the investigator's instructions.
- •Patients who voluntarily provided written informed consent, or whose legally authorized representative provided written informed consent, to participate in this clinical trial.
排除标准
- •Patients with a history of ophthalmic surgery that may affect the absorption, distribution, or excretion of the investigational product, including cataract surgery, phakic intraocular lens (IOL) surgery, corneal inlay surgery, radial keratotomy (RK), or other intraocular surgeries.
- •Patients with a history of LASIK, LASEK, or PRK (Photorefractive Keratectomy) within one year prior to screening.
- •Patients with a history of hypersensitivity to the components of the investigational product or other cholinergic agonist drugs.
- •Patients with the following conditions known to require cautious administration of the investigational product components:
- •Bronchial asthma, heart failure, Parkinson's disease.
- •Gastrointestinal (GI) stenosis (e.g., intestinal obstruction), duodenal ulcer, GI spasms, or clinically significant defecation disorders due to constipation.
- •Urinary tract obstruction due to urinary tract disorders.
- •Patients who have received at least one dose of another investigational product within 30 days prior to participation in this clinical trial.
- •Patients deemed inappropriate by the investigator due to other diseases or conditions that may affect the evaluation of the efficacy or safety of the clinical trial.
研究组 & 干预措施
Placebo
Placebo Comparator
Vehicle
干预措施: Vehicle (Placebo solution) (Drug)
CTO0307
Experimental
CTO0307 Ophthalmic Solution
干预措施: CTO0307 Eye drop (Drug)
结局指标
主要结局
Percentage of Participants Gaining 3 Lines or More in DCNVA
时间窗: Week 4
The proportion of patients who achieved an improvement of ≥3 lines from baseline in DCNVA (Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity) at post-dose
次要结局
- Percentage of Participants Gaining 2 Lines or More in DCNVA at Week 4(Week 4)
- Percentage of Participants with DCNVA of >20/40 at Week 4(Week 4)
- Percentage of Participants with improvement in Patient Global Impression of Change (PGIC) at Week 4.(Week 4)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Assessment of visual outcomes of a new trifocal intraocular lens for distance, intermediate and near visual acuity.CTRI/2024/08/071812Biotech vision care pvt ltd216
进行中（未招募）
Unknown
Post-marketing clinical study to assess clinical performance and safety of EYECRYL Sert intraocular lens (IOL) versus TECNIS EyhanceTM IOL in patients with planned age-related cataract surgery.CTRI/2024/02/062774Biotech Vision Care Pvt Ltd134
招募中
不适用
Evaluating Presbyopia-Correcting IOLs in Complex Cataract Cases With Anterior Segment AbnormalitiesNCT07321756Second Affiliated Hospital, School of Medicine, Zhejiang University320
已完成
不适用
Clinical Outcomes of Femtosecond Laser Presbyopia Treatment in Monofocal IOLsPresbyopiaNCT07384182Perfect Lens, LLC19
尚未招募
3 期
Effectiveness of chakshushya basti in NearsightednessCTRI/2026/04/109007Dr Ajinkya Kondekar110